Skip to content

US · HSCS · MEDICAL - DEVICES

HeartSciences Inc. (HSCS) intrinsic value and stock valuation

$1.81as of 2026-11-21 · Mkt cap 4.92M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

HeartSciences Inc. DCF and intrinsic value

InvestorsCraft values HSCS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from HSCS’s statements →

HeartSciences Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Southlake, TX 76092 heartsciences.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-9.14M
20202025
Free cash flow
-$-7.47M
20202025
Total equity
$225.5M
20202026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20262025202420232022
Revenue—$0.00$20K$10K$10K
Operating income—-$-8.41M-$-6.31M-$-6.11M-$-4.71M
Net income—-$-9.14M-$-6.61M-$-6.35M-$-4.83M
EPSd—-$-3.48M-$-18.89M-$-79.38M-$-161M
Operating cash flow—-$-7.43M-$-6.07M-$-5.77M-$-3.64M
Capital expenditure—-$-40K-$-130K-$-20K-$0.00
Free cash flow—-$-7.47M-$-6.2M-$-5.79M-$-3.65M
Total assets$5.26B$4.22M$9.5M$3.29M$2.09M
Total debt$3.94B$2.99M$1.04M$1.57M$6.16M
Net debt$2.28B$1.89M-$-4.77M-$-90K$5.24M
Total equity$225.5M$210K$7.32M$230K-$-6.06M
Cash and short-term investments$1.66B$1.1M$5.81M$1.66M$920K
Income statement
20252024202320222021
Revenue$0.00$20K$10K$10K$30K
Cost of revenue$130K$100K$30K$30K$40K
Gross profit-$-130K-$-80K-$-20K-$-20K-$-20K
Research and development expenses$2.84B$2.88M$2.46M$3M$1.71M
Selling, general and administrative expenses$5.58B$3.34M$3.63M$1.69M$840K
Other expenses-$-8.41B$0.00$0.00$0.00$0.00
Operating expenses$8.28M$6.22M$6.09M$4.69M$2.55M
Cost and expenses$8.42M$6.32M$6.12M$4.72M$2.59M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$750K$350K$240K$370K$130K
Depreciation and amortization$0.00$100K$30K$30K$30K
Ebitda-$-8.41M-$-6.16M-$-6.08M-$-4.43M-$-2.29M
Operating income-$-8.41M-$-6.31M-$-6.11M-$-4.71M-$-2.57M
Total other income/expenses, net-$-730K-$-300K-$-240K-$-120K$120K
Income before tax-$-9.14M-$-6.61M-$-6.35M-$-4.83M-$-2.45M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-9.14M-$-6.61M-$-6.35M-$-4.83M-$-2.45M
Weighted average shares outstanding$2.63M$350K$80K$30K$30K
Weighted average diluted shares outstanding$2.63M$350K$80K$30K$30K
Balance sheet
20262025202420232022
Cash and short-term investments$1.66B$1.1M$5.81M$1.66M$920K
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$655.6M$650K$630K$680K$670K
Total current assets$2.58B$2.17M$7.35M$2.7M$1.93M
Property, plant and equipment, net$307.4M$440K$560K$590K$160K
Goodwill and intangible assets$2.37B$1.62M$1.59M$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.68B$2.05M$2.15M$590K$160K
Total assets$5.26B$4.22M$9.5M$3.29M$2.09M
Accounts payable$318.3M$320K$450K$630K$690K
Short-term debt$3.76B$2.67M$600K$530K$1.72M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.86B$3.7M$1.75M$1.83M$3.47M
Long-term debt$175.5M$310K$430K$1.04M$4.44M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$175.5M$310K$430K$1.22M$4.67M
Capital lease obligations$314.5M$430K$540K$570K$90K
Total liabilities$5.04B$4.02M$2.19M$3.06M$8.15M
Common stock$3.19M$0.00$0.00$0.00$0.00
Retained earnings-$-85.27B-$-76.13M-$-67.36M-$-60.76M-$-54.4M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$225.5M$210K$7.32M$230K-$-6.06M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$3.94B$2.99M$1.04M$1.57M$6.16M
Net debt$2.28B$1.89M-$-4.77M-$-90K$5.24M
Cash flow statement
20252024202320222021
Net income-$-9.14M-$-6.61M-$-6.35M-$-4.83M-$-2.45M
Depreciation and amortization$130K$100K$140K$30K$30K
Stock-based compensation$1.31M$410K$250K$70K$20K
Change in working capital-$-1.08M-$-500K$70K$1.12M$190K
Accounts receivable$0.00$0.00$0.00-$0.00$0.00
Inventory-$-10K$50K-$0.00$80K$110K
Accounts payable-$0.00-$-180K$40K$360K-$-20K
Net cash provided by operating activities-$-7.43M-$-6.07M-$-5.77M-$-3.64M-$-2.45M
Investments in property, plant and equipment-$0.00-$-60K-$-20K-$0.00-$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-40K-$-130K-$-20K-$0.00-$0.00
Common stock issued$170K$10.3M$5.62M$0.00$200K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.03M$10.3M$6.53M$3.84M$2.68M
Net change in cash$560K$4.15M$740K$190K$230K
Cash at end of period$1.66M$5.81M$1.66M$920K$720K
Operating cash flow-$-7.43M-$-6.07M-$-5.77M-$-3.64M-$-2.45M
Capital expenditure-$-40K-$-130K-$-20K-$0.00-$0.00
Free cash flow-$-7.47M-$-6.2M-$-5.79M-$-3.65M-$-2.45M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About HeartSciences Inc.

        HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.

        CEO
        Andrew Simpson
        Employees
        14
        Beta
        1.79

        Explore

        Frequently asked questions

        What is the intrinsic value of HeartSciences Inc. (HSCS)?

        HeartSciences Inc. (HSCS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is HSCS undervalued?

        HSCS trades at a price of $1.81 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.